GKOS - Glaukos Corporation

Glaukos Announces Participation in Upcoming Investor Conferences

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences: Stifel Virtual Ophthalmology Forum on Tuesday, May 26, 2026, at 1:30 p.m. ET William Blair 46th Annual Growth Stock Conference on Tuesday, June 2, 2026, at.

May 12, 2026 03:00 AM • businesswire.com

Glaukos Gains on Q1 Earnings Beat & Improved 2026 Revenue Outlook

GKOS beats Q1 estimates with 41% revenue growth, narrows loss and raises 2026 outlook as glaucoma and corneal segments drive momentum.

Apr 30, 2026 07:55 AM • zacks.com

Glaukos Corporation (GKOS) Q1 2026 Earnings Call Transcript

Glaukos Corporation (GKOS) Q1 2026 Earnings Call Transcript

Apr 29, 2026 07:21 PM • seekingalpha.com

Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Glaukos (GKOS) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Apr 29, 2026 06:00 PM • zacks.com

Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates

Glaukos (GKOS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.22 per share a year ago.

Apr 29, 2026 03:41 PM • zacks.com

Glaukos Announces First Quarter 2026 Financial Results

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the first quarter ended March 31, 2026. Key highlights include: Record net sales of $150.6 million in Q1 2026 increased 41% year-over-year on a reported basis and 39% year-over-year on a constant currency basis. Glaucoma record ne.

Apr 29, 2026 12:05 PM • businesswire.com

Glaukos Wins Permanent J-Code for Epioxa Keratoconus Therapy

GKOS secures a permanent CMS J-code for Epioxa, a move set to streamline reimbursement and expand patient access in keratoconus treatment.

Apr 16, 2026 07:26 AM • zacks.com

Glaukos Announces the Release of its 2025 Sustainability Report

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that it has published its 2025 Sustainability Report. The report highlights the company's continued commitment and progress on its key corporate sustainability priorities. The Sustainability Report can be found on the company's website here. “I am prou.

Apr 16, 2026 03:00 AM • businesswire.com

Glaukos Receives Permanent J-code for Epioxa™

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today the U.S. Centers for Medicare and Medicaid Services (CMS) has assigned a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code for Epioxa™ HD / Epioxa™ (“Epioxa”) for the treatment of keratoconus, a rare, sight-threatening disease.

Apr 15, 2026 12:05 PM • businesswire.com

Glaukos to Release First Quarter 2026 Financial Results after Market Close on April 29

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, plans to release first quarter 2026 financial results after the market close on Wednesday, April 29, 2026. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on April 29, 2026. A link to t.

Apr 08, 2026 03:00 AM • businesswire.com

Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held April 10-13, 2026 in Washington, D.C. Glaukos will be exhibiting onsite at booth #407.

Apr 06, 2026 03:00 AM • businesswire.com

Capricorn Fund Managers Ltd Invests $6.78 Million in Glaukos Corporation $GKOS

Capricorn Fund Managers Ltd bought a new stake in shares of Glaukos Corporation (NYSE: GKOS) during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 60,000 shares of the medical instruments supplier's stock, valued at approximately $6,775,000. Glaukos accounts

Apr 06, 2026 12:43 AM • defenseworld.net

Reviewing Anteris Technologies Global (NASDAQ:AVR) and Glaukos (NYSE:GKOS)

Glaukos (NYSE: GKOS - Get Free Report) and Anteris Technologies Global (NASDAQ: AVR - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, profitability, valuation and earnings. Volatility and Risk Glaukos has a beta of

Apr 05, 2026 09:24 PM • defenseworld.net

Glaukos Corporation $GKOS Shares Acquired by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC lifted its position in shares of Glaukos Corporation (NYSE: GKOS) by 32.8% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 355,279 shares of the medical instruments supplier's stock after acquiring an additional 87,781 shares during

Apr 02, 2026 11:10 PM • defenseworld.net

Glaukos (NYSE:GKOS) CFO Sells $267,321.06 in Stock

Glaukos Corporation (NYSE: GKOS - Get Free Report) CFO Alex Thurman sold 2,511 shares of the firm's stock in a transaction that occurred on Wednesday, March 25th. The shares were sold at an average price of $106.46, for a total value of $267,321.06. Following the completion of the sale, the chief financial officer directly owned 41,967

Mar 28, 2026 12:29 AM • defenseworld.net

Glaukos Launches Epioxa, Boosts Growth in Corneal Treatments

GKOS launches Epioxa, the first FDA-approved topical keratoconus therapy, targeting an underserved market and positioning the company for long-term growth.

Mar 20, 2026 06:35 AM • zacks.com

Glaukos Corporation (NYSE:GKOS) Given Average Rating of “Moderate Buy” by Brokerages

Glaukos Corporation (NYSE: GKOS - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the sixteen brokerages that are currently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation, twelve have issued a buy recommendation and one has

Mar 19, 2026 10:44 PM • defenseworld.net

Why Is Glaukos (GKOS) Down 14.7% Since Last Earnings Report?

Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock?

Mar 19, 2026 08:31 AM • zacks.com

Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today the commercial availability of Epioxa™ HD / Epioxa™ (“Epioxa”), a groundbreaking advancement in corneal cross-linking for the treatment of keratoconus, a rare, sight-threatening corneal disease that is currently far too often undiagnosed and untreated.

Mar 19, 2026 03:00 AM • businesswire.com

Capital International Investors Buys 264,971 Shares of Glaukos Corporation $GKOS

Capital International Investors raised its stake in Glaukos Corporation (NYSE: GKOS) by 107.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 511,510 shares of the medical instruments supplier's stock after acquiring an additional 264,971 shares during the period. Capital International Investors

Mar 13, 2026 12:13 AM • defenseworld.net

Glaukos Corporation (GKOS) PT Raised to $162 at BTIG

$162.00 (was $143.82)

Ryan Zimmerman · BTIG

May 21, 2026 05:34 AM • StreetInsider

Glaukos price target raised to $170 from $160 at Stifel

$170.00 (was $135.57)

Thomas Stephan · Stifel Nicolaus

Apr 30, 2026 08:27 AM • TheFly

Glaukos price target raised to $141 from $131 at BTIG

$141.00 (was $116.96)

BTIG

Apr 30, 2026 07:24 AM • TheFly

Glaukos price target raised to $136 from $127 at Needham

$136.00 (was $116.96)

Needham

Apr 30, 2026 07:16 AM • TheFly

Glaukos price target raised to $127 from $125 at Needham

$127.00 (was $106.64)

David Saxon · Needham

Feb 18, 2026 07:18 AM • TheFly

Glaukos price target raised to $135 from $122 at Wells Fargo

$135.00 (was $106.64)

Wells Fargo

Feb 18, 2026 06:25 AM • TheFly

Glaukos price target raised to $131 from $123 at BTIG

$131.00 (was $125.46)

BTIG

Jan 28, 2026 12:18 PM • TheFly

Glaukos price target raised to $160 from $115 at Stifel

$160.00 (was $124.16)

Stifel Nicolaus

Jan 22, 2026 07:32 AM • TheFly

Piper Sandler on Glaukos Corporation (GKOS): 'Strong Q4 Print Overshadowed Some By iDose Buy-Side Bogey'

$165.00 (was $100.61)

Piper Sandler

Jan 14, 2026 07:59 AM • StreetInsider

Glaukos price target raised to $138 from $112 at Goldman Sachs

$138.00 (was $114.15)

Goldman Sachs

Jan 09, 2026 05:49 AM • TheFly

Glaukos price target raised to $145 from $115 at Stephens

$145.00 (was $112.91)

Stephens

Jan 02, 2026 07:08 AM • TheFly

Glaukos price target raised to $145 from $140 at UBS

$145.00 (was $117.09)

UBS

Dec 23, 2025 07:04 AM • TheFly

Glaukos price target raised to $145 from $120 at Truist

$145.00 (was $115.85)

Truist Financial

Dec 18, 2025 09:10 AM • TheFly

Piper Sandler on Glaukos Corporation (GKOS): 'Our 2026 Top Idea'

$165.00 (was $113.76)

UBS

Dec 17, 2025 07:02 AM • StreetInsider

Piper Sandler on Glaukos Corporation (GKOS): 'Our 2026 Top Idea'

$61.00 (was $113.76)

Piper Sandler

Dec 17, 2025 07:02 AM • StreetInsider

Glaukos price target raised to $125 from $117 at Needham

$125.00 (was $108.82)

Needham

Dec 09, 2025 09:28 AM • TheFly

UBS Reiterates Buy Rating on Glaukos Corporation (GKOS)

$140.00 (was $86.22)

Danielle Antalffy · UBS

Nov 10, 2025 10:16 AM • StreetInsider

Truist on Glaukos Corporation (GKOS): 'Strong 3Q Beat Led by iDos'

$120.00 (was $96.81)

Richard Newitter · Truist Financial

Oct 30, 2025 10:01 AM • StreetInsider

Glaukos price target raised to $116 from $104 at BTIG

$116.00 (was $77.09)

BTIG

Oct 30, 2025 07:33 AM • TheFly

Glaukos price target raised to $122 from $120 at Wells Fargo

$122.00 (was $77.09)

Wells Fargo

Oct 30, 2025 06:29 AM • TheFly